Q2 FY2026 EarningsQ2 FY26 results were mixed relative to consensus: GAAP net loss of $4.12M was narrower than the $5.09M expected beat, while GAAP EPS of -$0.66 beat the $0.83 loss consensus due to significant share dilution. Revenue remained at zero, in line with expectations for this clinical-stage biotech. Despite the bottom-line beat, a 'Going Concern' qualification and a Nasdaq delisting notice due to the stock trading below $1.00 represent severe structural risks.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Fibrobiologics(FBLG) the Revenue is 0 (--%), Meet estimate;the EBIT is -4.033 M (+10.18%), Beat estimate;the EPS is -0.66 (+72.5%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B--
0.00B--
0.00B--%
EBITExceed expectations
-0.00B10.18%
-0.01B13.43%
+0.00B23.61%
EPSExceed expectations
-0.6672.50%
-0.8365.42%
+0.17007.08%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf